53044 recent Wall Street rating changes — with our own star rating shown next to every analyst we independently track.
Track the latest analyst rating changes from Wall Street brokerages: stock upgrades, downgrades and price-target revisions, updated through the day. Unlike a plain ratings feed, every change here is matched — where we can — to the analyst's independent track record on 13Foresight, so you can see at a glance whether the person behind the call has actually been accurate. Analysts we rank show a ★★★★☆ score and link to their full performance page; firms link to their pooled track record. Use the tabs below to filter by change type.
| When | Stock | Change | Analyst | Rating | Price Target |
|---|---|---|---|---|---|
|
Aug 12
14:16 UTC
|
ETOR
eToro Group
|
◎ Target | Alex Kramm ★★★★★ #146 | Neutral | $50.00→ $35.00-30.0% |
|
Aug 12
14:16 UTC
|
DPC
DPC
|
◎ Target | Ken Herbert not yet tracked | Outperform | $53.00→ $62.00+17.0% |
|
Aug 12
14:16 UTC
|
CVS
CVS Health
|
◎ Target | Lisa Gill ★★★★☆ #904 | Overweight | $111.00→ $118.00+6.3% |
|
Aug 12
14:16 UTC
|
CRM
Salesforce
|
◎ Target | Karl Keirstead ★★★★☆ #880 | Neutral | $185.00→ $210.00+13.5% |
|
Aug 12
14:16 UTC
|
CRC
California Resources
|
◎ Target | Josh Silverstein ★★★☆☆ #1591 | Buy | $70.00→ $67.00-4.3% |
|
Aug 12
14:16 UTC
|
COP
ConocoPhillips
|
◎ Target | Josh Silverstein ★★★☆☆ #1591 | Buy | $143.00→ $153.00+7.0% |
|
Aug 12
14:16 UTC
|
CINT
CI&T
|
◎ Target | Leonardo Olmos ★★★☆☆ #2235 | Buy | $7.20→ $6.20-13.9% |
|
Aug 12
14:16 UTC
|
CHRD
Chord Energy
|
◎ Target | Josh Silverstein ★★★☆☆ #1591 | Buy | $153.00→ $171.00+11.8% |
|
Aug 12
14:16 UTC
|
CAVA
CAVA Group
|
◎ Target | Christopher Carril ★★★☆☆ #1917 | Overweight | $110.00→ $95.00-13.6% |
|
Aug 12
14:16 UTC
|
CAVA
CAVA Group
|
◎ Target | Nick Setyan ★★★★☆ #940 | Neutral | $85.00→ $70.00-17.6% |
|
Aug 12
14:16 UTC
|
CAH
Cardinal Health
|
◎ Target | Kevin Caliendo ★★★★☆ #573 | Buy | $274.00→ $280.00+2.2% |
|
Aug 12
14:16 UTC
|
CAH
Cardinal Health
|
◎ Target | Steven Valiquette ★★★☆☆ #1593 | Outperform | $240.00→ $250.00+4.2% |
|
Aug 12
14:16 UTC
|
BMBL
Bumble
|
◎ Target | Stephen Ju ★★☆☆☆ #2489 | Neutral | $4.50→ $3.00-33.3% |
|
Aug 12
14:16 UTC
|
BCAX
Bicara Therapeutics
|
◎ Target | Joseph Catanzaro ★★☆☆☆ #2485 | Neutral | $18.00→ $20.00+11.1% |
|
Aug 12
14:16 UTC
|
BBIO
BridgeBio Pharma
|
◎ Target | Anupam Rama ★★☆☆☆ #2747 | Overweight | $100.00→ $111.00+11.0% |
|
Aug 12
14:16 UTC
|
ATI
ATI
|
◎ Target | Michael Leshock ★☆☆☆☆ #3060 | Overweight | $211.00→ $258.00+22.3% |
|
Aug 12
14:16 UTC
|
ARMK
Aramark
|
◎ Target | Joshua Chan ★★★☆☆ #1530 | Buy | $67.00→ $71.00+6.0% |
|
Aug 12
14:16 UTC
|
APC
Anadarko Petroleum
|
◎ Target | Josh Silverstein ★★★☆☆ #1591 | Buy | $22.00→ $21.00-4.5% |
|
Aug 12
14:16 UTC
|
AMTM
Amentum
|
◎ Target | Ken Herbert not yet tracked | Sec→ r Perform | $28.00→ $26.00-7.1% |
|
Aug 12
14:16 UTC
|
AII
American Integrity Insurance Group
|
◎ Target | Matthew J. Carletti not yet tracked | Market Outperform | $25.00→ $26.00+4.0% |
|
Aug 12
14:16 UTC
|
ACM
AECOM
|
◎ Target | Sangita Jain ★★☆☆☆ #2732 | Overweight | $101.00→ $79.00-21.8% |
|
Aug 12
14:16 UTC
|
OKTA
Okta
|
↑ Upgrade | Rustam Kanga ★★★☆☆ #1111 | Market Perform→ Outperform | $170.00 |
|
Aug 12
13:15 UTC
|
SMCI
Super Micro Computer
|
◎ Target | Matt Bryson ★★★☆☆ #2004 | Neutral | $34.00→ $40.00+17.6% |
|
Aug 12
13:15 UTC
|
SE
SEA
|
◎ Target | Fawne Jiang ★☆☆☆☆ #3133 | Buy | $140.00→ $175.00+25.0% |
|
Aug 12
13:15 UTC
|
HBIO
Harvard Bioscience
|
◎ Target | Bruce D. Jackson not yet tracked | Speculative Buy | $6.00→ $7.50+25.0% |
|
Aug 12
13:15 UTC
|
EXE
Expand Energy
|
◎ Target | Subash Chandra ★★☆☆☆ #2577 | Buy | $124.00→ $109.00-12.1% |
|
Aug 12
13:15 UTC
|
BKKT
Bakkt
|
◎ Target | Mark Palmer ★★★★☆ #755 | Buy | $19.00→ $12.00-36.8% |
|
Aug 12
13:15 UTC
|
AXSM
Axsome Therapeutics
|
◎ Target | Graig Suvannavejh ★★☆☆☆ #2757 | Outperform | $306.00→ $316.00+3.3% |
|
Aug 12
13:15 UTC
|
AR
Antero Resources
|
◎ Target | Subash Chandra ★★☆☆☆ #2577 | Buy | $44.00→ $47.00+6.8% |
|
Aug 12
13:15 UTC
|
APA
APA
|
◎ Target | Subash Chandra ★★☆☆☆ #2577 | Buy | $40.00→ $46.00+15.0% |
|
Aug 12
13:15 UTC
|
ANF
Abercrombie & Fitch
|
◎ Target | Mauricio Serna ★★★★★ #290 | Buy | $136.00→ $153.00+12.5% |
|
Aug 12
13:15 UTC
|
AMTM
Amentum
|
◎ Target | Gavin Parsons ★★★☆☆ #1665 | Neutral | $23.00→ $24.00+4.3% |
|
Aug 12
13:15 UTC
|
AMCX
AMC Networks
|
◎ Target | John Hodulik ★★☆☆☆ #2386 | Sell | $6.00→ $10.00+66.7% |
|
Aug 12
13:15 UTC
|
AMBQ
Ambiq Micro
|
◎ Target | Timothy Arcuri ★★★☆☆ #1965 | Neutral | $70.00→ $73.00+4.3% |
|
Aug 12
13:05 UTC
|
ZURA
Zura Bio
|
◎ Target | Yatin Suneja ★☆☆☆☆ #2914 | Buy | $15.00→ $20.00+33.3% |
|
Aug 12
13:05 UTC
|
WDAY
Workday
|
◎ Target | Michael Turrin ★★★☆☆ #1104 | Overweight | $185.00→ $215.00+16.2% |
|
Aug 12
13:05 UTC
|
VG
Venture Global
|
◎ Target | Praneeth Satish ★★★☆☆ #1996 | Equal Weight | $14.00→ $15.00+7.1% |
|
Aug 12
13:05 UTC
|
TNGX
Tango Therapeutics
|
◎ Target | Michael Schmidt ★★☆☆☆ #2309 | Buy | $32.00→ $35.00+9.4% |
|
Aug 12
13:05 UTC
|
TEVA
Teva Pharmaceutical Industries
|
◎ Target | Glen Santangelo ★★★☆☆ #1082 | Overweight | $40.00→ $42.00+5.0% |
|
Aug 12
13:05 UTC
|
SMCI
Super Micro Computer
|
◎ Target | Sajal Dogra not yet tracked | Buy | $45.00→ $51.00+13.3% |
|
Aug 12
13:05 UTC
|
SFD
Smithfield Foods
|
◎ Target | Benjamin Theurer ★★★☆☆ #1218 | Overweight | $32.00→ $31.00-3.1% |
|
Aug 12
13:05 UTC
|
SEPN
Septerna
|
◎ Target | Derek Archila ★★★☆☆ #2083 | Overweight | $48.00→ $50.00+4.2% |
|
Aug 12
13:05 UTC
|
RIG
Transocean
|
◎ Target | Eddie Kim ★★★☆☆ #1693 | Overweight | $8.00→ $7.00-12.5% |
|
Aug 12
13:05 UTC
|
PGNY
Progyny
|
◎ Target | Peter Warendorf ★★★★★ #294 | Equal Weight | $34.00→ $30.00-11.8% |
|
Aug 12
13:05 UTC
|
ONON
ON
|
◎ Target | Adrienne Yih ★★★☆☆ #1627 | Overweight | $46.00→ $42.00-8.7% |
|
Aug 12
13:05 UTC
|
NTRA
Natera
|
◎ Target | Subbu Nambi ★★★★★ #21 | Buy | $290.00→ $360.00+24.1% |
|
Aug 12
13:05 UTC
|
NGNE
Neurogene
|
◎ Target | Debjit Chattopadhyay ★☆☆☆☆ #3170 | Buy | $69.00→ $81.00+17.4% |
|
Aug 12
13:05 UTC
|
MSFT
Microsoft
|
◎ Target | Michael Turrin ★★★☆☆ #1104 | Overweight | $650.00→ $700.00+7.7% |
|
Aug 12
13:05 UTC
|
LEGN
Legend Biotech
|
◎ Target | Etzer Darout ★★★☆☆ #979 | Overweight | $80.00→ $78.00-2.5% |
|
Aug 12
13:05 UTC
|
LBRX
LB Pharmaceuticals
|
◎ Target | Malcolm Hoffman not yet tracked | Outperform | $46.00→ $54.00+17.4% |
An analyst rating change is when a Wall Street brokerage updates its recommendation on a stock — an upgrade (e.g. Hold → Buy), a downgrade (e.g. Buy → Sell), or a price-target revision (raising or lowering the expected share price). This page lists the most recent changes across U.S. markets.
Where we independently track the analyst, each change shows our own star rating and accuracy rank, computed from real historical price performance — not the brokerage's own marketing. That lets you judge whether the analyst behind a call has actually been right before.
The feed refreshes several times a day, so new upgrades, downgrades and price-target changes appear the same day they are published. Each row shows the date and time we recorded it.
No. A rating change is one analyst's opinion, not investment advice. Track records vary widely — which is exactly why we attach each analyst's independent accuracy. Always do your own research.